Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations

BGJ398, a potent and selective pan-fibroblast growth factor receptor (FGFR) antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The maj...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Pal, Sumanta K., Rosenberg, Jonathan E., Hoffman-Censits, Jean H., Berger, Raanan, Quinn, David I., Galsky, Matthew D., Wolf, Juergen, Dittrich, Christian, Keam, Bhumsuk, Delord, Jean-Pierre, Schellens, Jan H. M., Gravis, Gwenaelle, Medioni, Jacques, Maroto, Pablo, Sriuranpong, Virote, Charoentum, Chaiyut, Burris, Howard A., Grünwald, Viktor, Petrylak, Daniel, Vaishampayan, Ulka, Gez, Eliahu, De Giorgi, Ugo, Lee, Jae-Lyun, Voortman, Jens, Gupta, Sumati, Sharma, Sunil, Mortazavi, Amir, Vaughn, David J., Isaacs, Randi, Parker, Katie, Chen, Xueying, Yu, Kun, Porter, Dale, Porta, Diana Graus, Bajorin, Dean F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6716598/
https://ncbi.nlm.nih.gov/pubmed/29848605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0229
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados